Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 4,240 Shares of Company Stock

Key Points

• Insider sale: Manuela Valente sold 4,240 SOPHiA GENETICS shares for $34,471 under a pre-arranged Rule 10b5-1 plan to cover tax obligations, reducing her stake by 2.01% to 206,210 shares.
• Stock and financial performance: SOPH recently traded at $7.15, with a 12-month range of $3.75 to $8.98. The company reported quarterly revenue of $23.31 million but missed earnings expectations, posting an EPS loss of $0.26.
• Analyst outlook: Analysts have a consensus “Hold” rating and an average price target of $10.00, while individual targets range as high as $14.00; institutional investors own 31.59% of the company.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Manuela Valente sold 4,240 shares of SOPHiA GENETICS stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $8.13, for a total value of $34,471.20. Following the completion of the sale, the insider directly owned 206,210 shares of the company's stock, valued at approximately $1,676,487.30. This trade represents a 2.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH traded down $0.23 during trading on Wednesday, hitting $7.15. 432,750 shares of the company's stock traded hands, compared to its average volume of 308,157. The stock has a market capitalization of $599.81 million, a price-to-earnings ratio of -6.22 and a beta of 0.95. SOPHiA GENETICS SA has a 12-month low of $3.75 and a 12-month high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The business has a 50 day moving average of $7.82 and a 200-day moving average of $6.12.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to analysts' expectations of $21.72 million. As a group, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. First Dallas Securities Inc. bought a new position in SOPHiA GENETICS in the 1st quarter valued at $50,000. Royal Bank of Canada increased its holdings in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after purchasing an additional 18,781 shares during the period. AXQ Capital LP purchased a new stake in shares of SOPHiA GENETICS in the second quarter worth $119,000. Silverberg Bernstein Capital Management LLC raised its position in shares of SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company's stock worth $257,000 after buying an additional 4,155 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in SOPHiA GENETICS during the second quarter valued at $567,000. Institutional investors own 31.59% of the company's stock.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
• Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
• Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing

Analysts Set New Price Targets

SOPH has been the topic of a number of analyst reports. HC Wainwright boosted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. BTIG Research lifted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Finally, Zacks Research raised SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of "Hold" and an average target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.